Unlock stock picks and a broker-level newsfeed that powers Wall Street.

Helsinki - Free Realtime Quote EUR

Nanoform Finland Oyj (NANOFH.HE)

1.0360
-0.0040
(-0.38%)
As of 4:34:55 PM GMT+3. Market Open.
Currency in EUR All numbers in thousands
Download
Breakdown
TTM
12/31/2024
12/31/2023
12/31/2022
12/31/2021
Total Revenue
2,777.5020
2,777.5020
2,566.4850
3,487.3760
1,954.5470
Cost of Revenue
551.9810
551.9810
849.0430
340.4930
162.3750
Gross Profit
2,225.5210
2,225.5210
1,717.4420
3,146.8830
1,792.1720
Operating Expense
26,415.8760
26,415.8760
24,193.0040
24,555.9740
21,497.5260
Operating Income
-24,190.3550
-24,190.3550
-22,475.5620
-21,409.0910
-19,705.3540
Net Non Operating Interest Income Expense
1,465.1170
1,465.1170
1,547.2900
-47.0650
-757.8870
Pretax Income
-23,397.4820
-23,397.4820
-20,732.6410
-22,055.8220
-19,687.0460
Tax Provision
30.4450
30.4450
23.2330
19.0260
2.6130
Net Income Common Stockholders
-23,427.9270
-23,427.9270
-20,755.8740
-22,074.8480
-19,689.6590
Diluted NI Available to Com Stockholders
-23,427.9270
-23,427.9270
-20,755.8740
-22,074.8480
-19,689.6590
Basic EPS
-0.27
-0.28
-0.26
-0.29
-0.29
Diluted EPS
-0.27
-0.28
-0.26
-0.29
-0.29
Basic Average Shares
83,944.8420
83,303.5120
78,419.3060
77,031.3020
68,136.5960
Diluted Average Shares
83,944.8420
83,303.5120
78,419.3060
77,031.3020
68,136.5960
Total Operating Income as Reported
-24,235.6330
-24,235.6330
-22,475.5620
-21,409.0890
-19,705.3540
Total Expenses
26,967.8570
26,967.8570
25,042.0470
24,896.4670
21,659.9010
Net Income from Continuing & Discontinued Operation
-23,427.9270
-23,427.9270
-20,755.8740
-22,074.8480
-19,689.6590
Normalized Income
-23,343.9310
-23,343.9310
-20,785.4708
-21,615.3456
-18,892.2542
Interest Income
1,685.6920
1,685.6920
1,749.8810
372.6880
25.3180
Interest Expense
41.4390
41.4390
6.8270
218.4310
535.2770
Net Interest Income
1,465.1170
1,465.1170
1,547.2900
-47.0650
-757.8870
EBIT
-23,356.0430
-23,356.0430
-20,725.8140
-21,837.3910
-19,151.7690
EBITDA
-20,181.1650
-20,181.1650
-17,847.6860
-19,455.6500
-17,191.4500
Reconciled Cost of Revenue
551.9810
551.9810
849.0430
340.4930
162.3750
Reconciled Depreciation
3,174.8780
3,174.8780
2,878.1280
2,381.7410
1,960.3190
Net Income from Continuing Operation Net Minority Interest
-23,427.9270
-23,427.9270
-20,755.8740
-22,074.8480
-19,689.6590
Total Unusual Items Excluding Goodwill
-104.9950
-104.9950
36.9960
-574.3780
-996.7560
Total Unusual Items
-104.9950
-104.9950
36.9960
-574.3780
-996.7560
Normalized EBITDA
-20,076.1700
-20,076.1700
-17,884.6820
-18,881.2720
-16,194.6940
Tax Rate for Calcs
0.0002
0.0002
0.0002
0.0002
0.0002
Tax Effect of Unusual Items
-20.9990
-20.9990
7.3992
-114.8756
-199.3512
12/31/2021 - 6/4/2020

Upgrade to begin using 40 years of financial statements and get so much more.

Perform in-depth fundamental analysis with decades of income statements, balance sheets, and cash flows — all exportable.

Upgrade

Related Tickers

4FR.BE Faron Pharmaceuticals Oy
2.3700
-2.87%
 
FARN.L Faron Pharmaceuticals Oy
201.50
-4.05%
 
SYNACT.ST SynAct Pharma AB
17.90
-0.56%
 
FARON.HE Faron Pharmaceuticals Oy
2.3900
-2.05%
 
OMGAQ Omega Therapeutics, Inc.
0.0470
+42.42%
 
PLRZ Polyrizon Ltd.
0.3300
-2.94%
 
ELAB PMGC Holdings Inc.
2.5400
-12.71%
 
GUBRA.CO Gubra A/S
351.20
-2.77%
 
DRMA Dermata Therapeutics, Inc.
0.7700
-2.83%
 
ARVN Arvinas, Inc.
9.12
+0.55%